Found: 39
Select item for more details and to access through your institution.
Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation.
- Published in:
- Angewandte Chemie, 2016, v. 128, n. 39, p. 12214, doi. 10.1002/ange.201606121
- By:
- Publication type:
- Article
Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [<sup>111</sup>In]In‐XYIMSR‐01 for phase I regulatory approval.
- Published in:
- Journal of Labelled Compounds & Radiopharmaceuticals, 2021, v. 64, n. 6, p. 243, doi. 10.1002/jlcr.3906
- By:
- Publication type:
- Article
A Unique Core–Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 2, p. 373, doi. 10.3390/pharmaceutics14020373
- By:
- Publication type:
- Article
Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation.
- Published in:
- Angewandte Chemie International Edition, 2016, v. 55, n. 39, p. 12035, doi. 10.1002/anie.201606121
- By:
- Publication type:
- Article
Tumor-specific expression and detection of a CEST reporter gene.
- Published in:
- Magnetic Resonance in Medicine, 2015, v. 74, n. 2, p. 544, doi. 10.1002/mrm.25748
- By:
- Publication type:
- Article
A radioligand for in vitro autoradiography of CSF1R in post-mortem CNS tissues.
- Published in:
- EJNMMI Research, 2024, v. 14, n. 1, p. 1, doi. 10.1186/s13550-024-01133-2
- By:
- Publication type:
- Article
A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 3, p. 405, doi. 10.3390/biom12030405
- By:
- Publication type:
- Article
Preclinical Evaluation of a New Series of Albumin-Binding 177 Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics.
- Published in:
- Molecules, 2023, v. 28, n. 16, p. 6158, doi. 10.3390/molecules28166158
- By:
- Publication type:
- Article
Imaging Brain Injury in Former National Football League Players.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 10, p. e2340580, doi. 10.1001/jamanetworkopen.2023.40580
- By:
- Publication type:
- Article
Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players.
- Published in:
- JAMA Neurology, 2017, v. 74, n. 1, p. 67, doi. 10.1001/jamaneurol.2016.3764
- By:
- Publication type:
- Article
PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP.
- Published in:
- EJNMMI Research, 2020, v. 10, n. 1, p. 1, doi. 10.1186/s13550-020-00657-7
- By:
- Publication type:
- Article
Salicylic Acid-Based Polymeric Contrast Agents for Molecular Magnetic Resonance Imaging of Prostate Cancer.
- Published in:
- Chemistry - A European Journal, 2018, v. 24, n. 28, p. 7235, doi. 10.1002/chem.201800882
- By:
- Publication type:
- Article
Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1432286
- By:
- Publication type:
- Article
A red-shifted fluorescent substrate for aldehyde dehydrogenase.
- Published in:
- Nature Communications, 2014, v. 5, n. 4, p. 3662, doi. 10.1038/ncomms4662
- By:
- Publication type:
- Article
Prostate‐specific membrane antigen‐targeted photoacoustic imaging of prostate cancer in vivo.
- Published in:
- Journal of Biophotonics, 2018, v. 11, n. 9, p. 1, doi. 10.1002/jbio.201800021
- By:
- Publication type:
- Article
An improved 211At-labeled agent for PSMA-targeted alpha therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262098
- By:
- Publication type:
- Article
An improved <sup>211</sup>At-labeled agent for PSMA-targeted alpha therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262098
- By:
- Publication type:
- Article
An improved <sup>211</sup>At-labeled agent for PSMA-targeted alpha therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262098
- By:
- Publication type:
- Article
An improved <sup>211</sup>At-labeled agent for PSMA-targeted alpha therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262098
- By:
- Publication type:
- Article
An improved <sup>211</sup>At-labeled agent for PSMA-targeted alpha therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.262098
- By:
- Publication type:
- Article
An improved <sup>211</sup>At-labeled agent for PSMA-targeted alpha therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.121.262098
- By:
- Publication type:
- Article
Preclinical evaluation of <sup>213</sup>Bi-/<sup>225</sup>Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.256388
- By:
- Publication type:
- Article
High availability of the α7 nicotinic acetylcholine receptor in brains of individuals with mild cognitive impairment: A pilot study using <sup>18</sup>F-ASEM PET.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.230979
- By:
- Publication type:
- Article
Preclinical evaluation of <sup>203/212</sup>Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.229393
- By:
- Publication type:
- Article
Biodistribution and Radiation Dosimetry of <sup>124</sup>I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation .
- Published in:
- Journal of Nuclear Medicine, 2018, v. 59, n. 11, p. 1751, doi. 10.2967/jnumed.117.207431
- By:
- Publication type:
- Article
<sup>18</sup>F-XTRA PET for Enhanced Imaging of the Extrathalamic α4β2 Nicotinic Acetylcholine Receptor.
- Published in:
- Journal of Nuclear Medicine, 2018, v. 59, n. 10, p. 1603, doi. 10.2967/jnumed.117.205492
- By:
- Publication type:
- Article
<sup>18</sup>F-FNDP for PET Imaging of Soluble Epoxide Hydrolase.
- Published in:
- Journal of Nuclear Medicine, 2016, v. 57, n. 11, p. 1817, doi. 10.2967/jnumed.116.173245
- By:
- Publication type:
- Article
(2S)-2-(3-(1-Carboxy-5-(4-<sup>211</sup>At-Astatobenzamido)Pentyl) Ureido)-Pentanedioic Acid for PSMA-Targeted a-Particle Radiopharmaceutical Therapy.
- Published in:
- Journal of Nuclear Medicine, 2016, v. 57, n. 10, p. 1569, doi. 10.2967/jnumed.116.174300
- By:
- Publication type:
- Article
Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.
- Published in:
- Journal of Nuclear Medicine, 2015, v. 56, n. 9, p. 1401, doi. 10.2967/jnumed.115.155929
- By:
- Publication type:
- Article
Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-89124-4
- By:
- Publication type:
- Article
A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-86551-1
- By:
- Publication type:
- Article
Tuning Phenols with Intra-Molecular Bond Shifted HYdrogens (IM-SHY) as diaCEST MRI Contrast Agents.
- Published in:
- Chemistry - A European Journal, 2014, v. 20, n. 48, p. 15824, doi. 10.1002/chem.201403943
- By:
- Publication type:
- Article
First-in-human imaging using [<sup>11</sup>C]MDTC: a radiotracer targeting the cannabinoid receptor type 2.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 8, p. 2386, doi. 10.1007/s00259-023-06170-y
- By:
- Publication type:
- Article
Correction to: Hetero-bivalent agents targeting FAP and PSMA.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Hetero-bivalent agents targeting FAP and PSMA.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 13, p. 4369, doi. 10.1007/s00259-022-05933-3
- By:
- Publication type:
- Article
First-in-human neuroimaging of soluble epoxide hydrolase using [<sup>18</sup>F]FNDP PET.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 10, p. 3122, doi. 10.1007/s00259-021-05231-4
- By:
- Publication type:
- Article
<sup>177</sup>Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2019, v. 46, n. 12, p. 2545, doi. 10.1007/s00259-019-04434-0
- By:
- Publication type:
- Article
In vitro characterization of pralidoxime transport and acetylcholinesterase reactivation across MDCK cells and stem cell-derived human brain microvascular endothelial cells (BC1-hBMECs).
- Published in:
- Fluids & Barriers of the CNS, 2016, v. 13, p. 1, doi. 10.1186/s12987-016-0035-0
- By:
- Publication type:
- Article
Non-invasive delivery of levodopa-loaded nanoparticles to the brain via lymphatic vasculature to enhance treatment of Parkinson's disease.
- Published in:
- Nano Research, 2021, v. 14, n. 8, p. 2749, doi. 10.1007/s12274-020-3280-0
- By:
- Publication type:
- Article